Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Brodalumab in Axial Spondyloarthritis
jRCT2080223394Phase 3Completed
- Sponsor
- Kyowa Kirin
- Start
- Nov 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in axial spondyloarthritis (axSpA) and ankylosing spondylitis (AS) comparing Brodalumab 210 mg Q2W with Placebo Q2W (2 arms). Started Nov 2016; status: completed.
02
Drugs
brodalumab
03
Conditions
axial spondyloarthritis (axSpA)ankylosing spondylitis (AS)
Beyond the preview
Go deeper on jRCT2080223394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223394.